Abstract:Lung cancer is one of the most common malignant tumors and has a poor prognosis and a low survival rate. Traditional treatments, such as radiotherapy and chemotherapy, still face some challenges because of high drug resistance and toxicity. Therefore, it is necessary to discover a new kind of targeted drug with low toxicity and high efficiency. CDK12 is a cell cycle-dependent kinase whose main function is to activate RNA polymerase II (RNAPII) and promote the transcriptional extension of RNA. However, the role and molecular mechanism of CDK12 in lung cancer are still unclear. In this study, the mutation and RNA-Seq data of CDK12 in lung adenocarcinoma and squamous cell carcinoma were downloaded from The Cancer Genome Atlas (TCGA) database and analyzed with the custom scripts. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) and cell colony formation assays. A subcutaneous tumor experiment in nude mice was used to examine the effects of CDK12 knockdown on the in vivo tumor growth of NSCLC cells. The cell cycle distribution and the apoptosis rate of lung cancer cells were assessed by flow cytometry. Regulation of TANK-binding kinase 1 (TBK1) by CDK12 was evaluated by quantitative PCR, immunoprecipitation and Western blot analysis. In this study we have analyzed the mutation and expression data of The Cancer Genome Atlas (TCGA) database and found that CDK12 is highly expressed in lung cancer tissues. Clinical correlation analysis showed that high expression of CDK12 in NSCLC reduces patient survival, but its high expression is only related to early tumor progression and has no significant correlation with late tumor progression and metastasis. Furthermore, we present evidence that CDK12 depletion in lung cancer cell lines not only leads to the inhibition of cell growth and induces apoptosis but also inhibits tumor growth of NSCLC cells in vivo. CDK12 positively regulates the expression of the oncogene TBK1 in lung cancer cells. These results revealed that CDK12 affects the progression of non-small cell lung cancer through positive regulation of TBK1 expression, suggesting that CDK12 might be a potential molecular target for the treatment of non-small cell lung cancer.

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery

CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer

Current progress and novel strategies that target CDK12 for drug discovery.

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

A Patent and Literature Review of CDK12 Inhibitors

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.

CDK12 is a Promising Therapeutic Target for the Transcription Cycle and DNA Damage Response in Metastatic Osteosarcoma.

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

Targeting CDK12 Obviates the Malignant Phenotypes of Colorectal Cancer Through the Wnt/β-catenin Signaling Pathway

CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration

Targeting CDK7 in oncology: The avenue forward.

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)

Targeting cyclin-dependent kinase 9 in cancer therapy

CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors

CDK9 inhibitors in cancer research

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition